Single-Center Experience With Third-Generation Cryoballoon Ablation for Atrial Fibrillation
Eastern Journal of Medicine, cilt.31, sa.3, ss.614-619, 2026 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 3
- Basım Tarihi: 2026
- Doi Numarası: 10.5505/ejm.2026.91297
- Dergi Adı: Eastern Journal of Medicine
- Derginin Tarandığı İndeksler: Scopus, EMBASE, TR DİZİN (ULAKBİM), Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Sayfa Sayıları: ss.614-619
- Anahtar Kelimeler: Atrial Fibrillation, Catheter Ablation, Cryoballoon Ablation, Third-Generation Cryoballoon
- İstanbul Medipol Üniversitesi Adresli: Evet
Özet
Atrial fibrillation (AF) continues to represent the most common form of persistent arrhythmia globally, with pulmonary vein isolation (PVI) serving as the principal method for rhythm control. The third-generation cryoballoon (CB3), engineered with a shorter distal tip, offers enhanced maneuverability and real-time feedback during ablation. We evaluated the safety, efficacy, and two-year outcomes of CB3-based pulmonary vein isolation (PVI) in atrial fibrillation patients under everyday clinical practice conditions. We performed a retrospective analysis of 164 patients with paroxysmal or persistent AF who underwent CB3-guided PVI between 2019 and 2022 at a high-volume electrophysiology center. Baseline clinical characteristics, procedural metrics, acute and de layed complications, and arrhythmia recurrence over 24 months were systematically evaluated. The mean age of the patients was 61.2 ± 12 years; 37.2% were female, and 69.5% presented with paroxysmal AF. The average LVEF was 61.1 ± 7.3%, and the mean left atrial diameter was 40.9 ± 5.1 mm. The mean procedure time was 43.0 ± 3.1 minutes, while the mean time to pulmonary vein isolation (TT-PVI) was 52.7 ± 16.3 seconds. Acute procedural complications occurred in 3.1% of patients, with transient phrenic nerve palsy being the most common adverse event. Atrial tachyarrhythmia recurrence occurred in 21.3% of patients during the 24-month follow-up. CB3-based cryoballoon ablation demonstrates high procedural efficiency, a low complication profile, and durable rhythm co ntrol over mid-term follow-up. These findings support CB3 as a reliable first-line strategy for AF ablation in contemporary clinical practice. Keyword.